儿童炎症性肠病归因直接费用的趋势:基于人群的分析
该研究基于加拿大曼尼托巴省1995至2017年行政数据,纳入733例18岁前诊断的儿童IBD患者及6763名匹配对照,分析IBD归因直接费用趋势。
要点
- 药物费用从1995年中位270加元增至2017年7944加元,是费用增长主要驱动因素。
- 医生服务费用从1995年中位381加元增至2017年936加元。
核心结论
- 二十余年间儿童IBD归因直接费用显著增加,主要由药物费用驱动。
研究设计与样本
- 基于人群的分析,数据来自曼尼托巴省健康提供者索赔等人口登记数据集(1995–2017年)。
- 纳入733例18岁前诊断的流行IBD病例(其中克罗恩病428例),随访2450人年。
主要发现
- 每患者年均医生服务计费费用中位数从1995年381加元(IQR 215–1064)增至2017年936加元(IQR 579–1932),P < 0.001。
- 每患者年均药物费用中位数从1995年270加元增至2017年7944加元,P < 0.0001。
临床怎么用
- 儿童IBD的财务负担随时间显著上升,药物费用是主要驱动因素,提示临床与政策层面需关注费用控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In addition to its morbidities, inflammatory bowel disease (IBD) has a major financial burden on patients and healthcare systems. However, there is a paucity of evidence on IBD-attributable costs in children. AIMS: To determine the trends of IBD-attributable direct costs over time using a population-based analysis. METHODS: Data were extracted from Manitoba Health Provider Claims and other population registry datasets from 1995 to 2017. Children with IBD were matched by age, sex and location with children without IBD. IBD-attributable direct costs were calculated using utilization counts from the administrative data and cost estimates from different sources. Inpatient hospitalisation and outpatient procedure costs were estimated using the resource intensity weight (RIW) that is attached to each record in the data. Costs were expressed in Canadian dollars. RESULTS: We included 733 (428 with Crohn's disease) prevalent cases who were diagnosed with IBD before the age of 18 years and were followed for 2450 person-years. A matched control group of 6763 persons who were followed for 21 558 person-years was included. The median annual costs of physician services billed per patient increased from $381 (IQR 215-1064) in 1995 to $936 (IQR 579-1932) in 2017 (P < 0.001). The annual medication costs per patient increased from a median of $270 in 1995 to $7944 in 2017 (P < 0.0001). The median annual direct cost per patient was $1810 in 2004 as compared to $14 791 (P < 0.0001) in 2017. CONCLUSIONS: Over two decades, there was a significant increase in the paediatric IBD-attributable direct costs mainly driven by medication costs.
引用
- El-Matary W, Nugent Z, Witt J, et al. Trends in paediatric inflammatory bowel disease-attributable direct costs: a population-based analysis. Aliment Pharmacol Ther. 2021. PMID: 33836105. doi:10.1111/apt.16358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。